DroneShield Stock And Other Financially Fit Penny Stocks Worth A Closer Look

Global interest rates are moving in different directions as central banks react to energy costs, inflation and growth. That is pushing more investors to look beyond blue chips and consider Financially Fit Penny Stocks. These are lower-priced companies with a focus on balance sheet strength. This article explains why that screen stands out today and highlights three stocks that may merit a closer look.

The three Financially Fit Penny Stocks in this article are just a starting sample, and the full screen surfaced 405 more companies with equally focused balance sheets and stories that are not covered here. If you want to go further, head straight into the Financially Fit Penny Stocks screener to identify, filter and analyze the highest conviction ideas that match your approach.

DroneShield (ASX:DRO)

DroneShield is a Sydney based defence technology company that sells counter drone hardware and software to militaries, security agencies and critical infrastructure operators. It generates about A$216.8 million in revenue from its Aerospace & Defense business, reflecting a focused exposure to the counter unmanned aircraft systems segment. The company has a market cap of about A$2 billion, which places it firmly in small to mid cap territory on the ASX.

DroneShield is attracting attention because it sits at the centre of a growing need to manage drones in defence and public safety, while recently moving from concept stock to profitable operator. Forecast earnings growth, fresh multi year defence contracts and a pipeline of repeat orders indicate the business is trying to transition to more stable revenue. However, the share price still reflects a history of lumpy results and low current ROE. Investors also need to weigh up governance questions, including a relatively new board and an ASIC investigation into past disclosures. For those comfortable with higher risk, the mix of profit momentum, specialised defence exposure and potential valuation upside means DroneShield may warrant closer consideration.

Profit momentum at DroneShield is only half the story. See how analysts frame the next phase of growth and what current forecasts imply for risk, contract dependence and valuation in the analyst forecasts for DroneShield

Build your own defence and balance sheet shortlist

DroneShield and the other two stocks in this list all came from a single screen, but the real value for you is in setting the filters yourself. Use our flexible Screener to blend valuation, balance sheet strength, growth outlook and risks into your own shortlist, or start with any of our curated Investing Ideas.

Sigma Healthcare (ASX:SIG)

Sigma Healthcare is a long established Australian pharmacy wholesaler and franchisor that supplies and supports community pharmacies, including Amcal and Discount Drug Stores, as well as providing logistics and health services. It generates about A$9.5b in revenue from its Healthcare segment and also sells products online. The company has a market cap of roughly A$34.3b, which places Sigma Healthcare among the larger listed groups on the ASX.

Sigma Healthcare sits at the centre of everyday medicine spending. Analysts expect earnings to grow 15% a year, and revenue is still forecast to rise even after a strong few years. That growth story comes with real tension. Profit margins have narrowed, the P/E is high and the company relies fully on external borrowing, all while a relatively new board and management team bed down. With the Boots takeover talks now off the table and focus back on the core Australian business, investors watching the upcoming August results may see either early confirmation that this reset is working, or fresh questions that the current valuation will have to answer.

Accelerating earnings expectations with a stretched P/E ratio makes Sigma Healthcare a live test of how much growth the market is really pricing in. Get the full context in the analyst forecasts for Sigma Healthcare

Mesoblast (ASX:MSB)

Mesoblast develops regenerative cell therapies for severe inflammatory and cardiovascular conditions using its mesenchymal lineage cell platform. It generates about US$65 million in revenue from the development of its cell technology platform for commercialization, and has a market cap of roughly A$2.9b, which puts it in mid cap territory on the ASX.

Mesoblast gives you rare exposure to an FDA approved cell therapy, Ryoncil, in pediatric steroid refractory acute graft versus host disease, with early commercial sales and fresh quarterly revenues that highlight growing use across major US centers. At the same time, the investment case still hinges on high stakes Phase 3 programs in chronic low back pain and heart failure, alongside a heavy funding need and losses that have required debt and could require more capital if trials slip. For investors who can handle that risk, the mix of a first in class product, large potential treatment markets and current analyst growth forecasts means Mesoblast is one to keep on the radar.

Mesoblast’s first in class cell therapy story is only half the picture. Analyst growth expectations, funding needs and trial timelines all intersect in ways many investors may be missing. See how the analyst forecasts for Mesoblast could change the risk reward balance.

Seeking Fresh Alternatives Before Others Do

Fresh opportunities can move from under the radar to flying fast once momentum builds. Use these focused stock lists before the crowd catches up and the best entry points drop.

• Spot income ideas with staying power by reviewing carefully filtered 4 dividend fortresses that put balance sheet strength and yield front and centre.
• Review the next wave of AI infrastructure by scanning curated 55 AI infrastructure stocks positioned to support rising data, power and chip demand.
• Get ahead of electrification trends by checking focused 8 top copper producer stocks supplying key metals for grids, vehicles and renewables while many investors are still looking elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com